O
KIDS icon

OrbiMed’s OrthoPediatrics KIDS Stock Holding History

OrbiMed’s Portfolio KIDS Stock Details KIDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-136,900
Closed -$3.65M – 157
2018
Q2 		$3.65M Sell
136,900
-288,300
-68% -$6.15M 0.04% 133
2018
Q1 		$6.4M Hold
425,200
– – 0.08% 114
2017
Q4 		$8.16M Buy
+425,200
New +$8.13M 0.1% 107

Other funds holding KIDS

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

OrbiMed's KIDS Position: Q3 2018 in Review

OrbiMed sold out of OrthoPediatrics (KIDS) in Q3 2018, closing a stake of 136,900 shares — an estimated $3.65M sold.

OrbiMed first reported a position in KIDS in Q4 2017 and held it in 3 quarters. The position peaked at $8.16M in Q4 2017. 63 funds tracked by Wall St. Rank hold KIDS as of Q3 2018.

  • OrbiMed reported no remaining OrthoPediatrics position as of Q3 2018 after selling out during the quarter.
  • OrbiMed sold 136,900 OrthoPediatrics shares in Q3 2018, an estimated $3.65M.
  • OrbiMed first reported a position in OrthoPediatrics in Q4 2017 and held it in 3 quarters.
  • OrbiMed's OrthoPediatrics position peaked at $8.16M in Q4 2017.
  • 63 funds tracked by Wall St. Rank held OrthoPediatrics as of Q3 2018.

Based on OrbiMed's 13F filing for Q3 2018, filed 14 Nov 2018.